{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:09:46Z","timestamp":1788487786387,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112507"],"award-info":[{"award-number":["70112507"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Brain metastases (BM) are an ever-increasing challenge in oncology, threatening quality of life and survival of many cancer patients. The majority of BM originate from lung adenocarcinoma, and stage III patients have a risk of 40\u201350% to develop BM in the first years of disease onset. As therapeutic options are limited, prevention of their occurrence is an attractive concept. Here we investigated whether Nintedanib (BIBF 1120), a tyrosine kinase inhibitor (TKI) targeting the VEGF pathway approved for lung adenocarcinoma, and the dual anti-VEGF-A\/Ang2 nanobody BI836880 have the potential to prevent BM formation. A mouse model of brain metastasis from lung adenocarcinoma was used in which tumor cells were injected intracardially. Metastases formation occurred inside and outside of the brain and was followed by MRI, IVIS, and immunohistochemistry. BM were reduced in volume and number by both Nintedanib and the dual anti-VEGF-A\/Ang2 nanobody, which translated into improved survival. Both compounds were able to normalize cerebral blood vessels at the site of brain metastatic lesions. Extracranial metastases, however, were not reduced, and meningeal metastases only partially. Interestingly, unspecific control IgG also lead to brain vessel normalization and reduction of brain and meningeal metastases. This data indicates a brain-specific group effect of antiangiogenic compounds with respect to metastasis prevention, most likely by preventing an early angiogenic switch. Thus, Nintedanib and BI836880 are promising candidates for future BM preventive study concepts in lung adenocarcinoma patients.<\/jats:p>","DOI":"10.1007\/s10585-020-10055-x","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T15:02:39Z","timestamp":1599922959000},"page":"637-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Nintedanib and a bi-specific anti-VEGF\/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells"],"prefix":"10.1007","volume":"37","author":[{"given":"Bogdana","family":"Kovalchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthia A.","family":"Karreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Piechutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Grosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael O.","family":"Breckwoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-6104","authenticated-orcid":false,"given":"Frank","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"issue":"1","key":"10055_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14(1):48\u201354. https:\/\/doi.org\/10.1007\/s11912-011-0203-y","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10055_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s12032-014-0400-2","volume":"32","author":"C Bachmann","year":"2014","unstructured":"Bachmann C, Schmidt S, Staebler A, Fehm T, Fend F, Schittenhelm J, Wallwiener D, Grischke E (2014) CNS metastases in breast cancer patients: prognostic implications of tumor subtype. Med Oncol 32(1):400. https:\/\/doi.org\/10.1007\/s12032-014-0400-2","journal-title":"Med Oncol"},{"issue":"3","key":"10055_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.trecan.2018.01.003","volume":"4","author":"M Valiente","year":"2018","unstructured":"Valiente M, Ahluwalia MS, Boire A, Brastianos PK, Goldberg SB, Lee EQ, Le Rhun E, Preusser M, Winkler F, Soffietti R (2018) The evolving landscape of brain metastasis. Trends Cancer 4(3):176\u2013196. https:\/\/doi.org\/10.1016\/j.trecan.2018.01.003","journal-title":"Trends Cancer"},{"issue":"7","key":"10055_CR4","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1200\/JCO.2005.04.123","volume":"23","author":"HJ Mamon","year":"2005","unstructured":"Mamon HJ, Yeap BY, Janne PA, Reblando J, Shrager S, Jaklitsch MT, Mentzer S, Lukanich JM, Sugarbaker DJ, Baldini EH, Berman S, Skarin A, Bueno R (2005) High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 23(7):1530\u20131537. https:\/\/doi.org\/10.1200\/JCO.2005.04.123","journal-title":"J Clin Oncol"},{"issue":"9","key":"10055_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Perol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, Investigators AT (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377(9):829\u2013838. https:\/\/doi.org\/10.1056\/NEJMoa1704795","journal-title":"N Engl J Med"},{"issue":"5","key":"10055_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/neuonc\/nov023","volume":"17","author":"S Puhalla","year":"2015","unstructured":"Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins C, Lockman P, McGregor J, Muldoon L, Nesbit G, Peereboom D, Smith Q, Walker S, Neuwelt E (2015) Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro-Oncology 17(5):639\u2013651. https:\/\/doi.org\/10.1093\/neuonc\/nov023","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10055_CR7","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","volume":"27","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27(10):1953\u20131958. https:\/\/doi.org\/10.1093\/annonc\/mdw289","journal-title":"Ann Oncol"},{"issue":"5","key":"10055_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459\u2013465. https:\/\/doi.org\/10.1016\/S1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"issue":"7","key":"10055_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976\u2013983. https:\/\/doi.org\/10.1016\/S1470-2045(16)30053-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"10055_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cncr.30946","volume":"124","author":"S Sloot","year":"2018","unstructured":"Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mule JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT (2018) Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer 124(2):297\u2013305. https:\/\/doi.org\/10.1002\/cncr.30946","journal-title":"Cancer"},{"issue":"8","key":"10055_CR11","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1078-0432.Ccr-14-2082","volume":"21","author":"B Besse","year":"2015","unstructured":"Besse B, Le Moulec S, Mazieres J, Senellart H, Barlesi F, Chouaid C, Dansin E, Berard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Lena H, Clement-Duchene C, Quantin X, Souquet PJ, Tredaniel J, Moro-Sibilot D, Perol M, Madroszyk AC, Soria JC (2015) Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res 21(8):1896\u20131903. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2082","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10055_CR12","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1078-0432.Ccr-14-2075","volume":"21","author":"YS Lu","year":"2015","unstructured":"Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL (2015) Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res 21(8):1851\u20131858. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2075","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10055_CR13","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542\u20132550. https:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"issue":"8","key":"10055_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27(8):1227\u20131234. https:\/\/doi.org\/10.1200\/JCO.2007.14.5466","journal-title":"J Clin Oncol"},{"issue":"4","key":"10055_CR15","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/1535-7163.MCT-15-0582","volume":"15","author":"A Ilhan-Mutlu","year":"2016","unstructured":"Ilhan-Mutlu A, Osswald M, Liao Y, Gommel M, Reck M, Miles D, Mariani P, Gianni L, Lutiger B, Nendel V, Srock S, Perez-Moreno P, Thorsen F, von Baumgarten L, Preusser M, Wick W, Winkler F (2016) Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther 15(4):702\u2013710. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0582","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10055_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11060-010-0200-2","volume":"100","author":"KC De Braganca","year":"2010","unstructured":"De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB (2010) Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 100(3):443\u2013447. https:\/\/doi.org\/10.1007\/s11060-010-0200-2","journal-title":"J Neurooncol"},{"issue":"2","key":"10055_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000360930","volume":"9","author":"AS Berghoff","year":"2014","unstructured":"Berghoff AS, Sax C, Klein M, Furtner J, Dieckmann K, Gatterbauer B, Widhalm G, Rudas M, Zielinski CC, Bartsch R, Preusser M (2014) Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report. Breast Care (Basel) 9(2):134\u2013136. https:\/\/doi.org\/10.1159\/000360930","journal-title":"Breast Care (Basel)"},{"key":"10055_CR18","volume-title":"Tumor angiogenesis: a key target for cancer therapy","author":"F Winkler","year":"2019","unstructured":"Winkler F (2019) Anti-angiogenics in brain metastases: perspectives and experiences. In: Marm\u00e9 D (ed) Tumor angiogenesis: a key target for cancer therapy. Springer, New York"},{"issue":"7","key":"10055_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMoa071780","volume":"357","author":"B Slotman","year":"2007","unstructured":"Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357(7):664\u2013672. https:\/\/doi.org\/10.1056\/NEJMoa071780","journal-title":"N Engl J Med"},{"issue":"3","key":"10055_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/jco.2010.29.1609","volume":"29","author":"EM Gore","year":"2011","unstructured":"Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29(3):272\u2013278. https:\/\/doi.org\/10.1200\/jco.2010.29.1609","journal-title":"J Clin Oncol"},{"issue":"3","key":"10055_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/1078155218798176","volume":"25","author":"M Lynch","year":"2019","unstructured":"Lynch M (2019) Preservation of cognitive function following whole brain radiotherapy in patients with brain metastases: complications, treatments, and the emerging role of memantine. J Oncol Pharm Pract 25(3):657\u2013662. https:\/\/doi.org\/10.1177\/1078155218798176","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10055_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijrobp.2010.05.013","volume":"81","author":"AH Wolfson","year":"2011","unstructured":"Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, Werner-Wasik M, Videtic GM, Garces YI, Choy H (2011) Primary analysis of a phase II randomized trial radiation therapy oncology group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 81(1):77\u201384. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.05.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10055_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nm.2072","volume":"16","author":"Y Kienast","year":"2010","unstructured":"Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16(1):116\u2013122. https:\/\/doi.org\/10.1038\/nm.2072","journal-title":"Nat Med"},{"issue":"7","key":"10055_CR24","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jtho.2018.03.032","volume":"13","author":"PH Feng","year":"2018","unstructured":"Feng PH, Chen KY, Huang YC, Luo CS, Wu SM, Chen TT, Lee CN, Yeh CT, Chuang HC, Han CL, Lin CF, Lee WH, Kuo CH, Lee KY (2018) Bevacizumab reduces S100A9-positive MDSCs linked to intracranial control in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol 13(7):958\u2013967. https:\/\/doi.org\/10.1016\/j.jtho.2018.03.032","journal-title":"J Thorac Oncol"},{"key":"10055_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2016.10.011","volume":"102","author":"NH Hanna","year":"2016","unstructured":"Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH (2016) Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial. Lung Cancer 102:65\u201373. https:\/\/doi.org\/10.1016\/j.lungcan.2016.10.011","journal-title":"Lung Cancer"},{"key":"10055_CR26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0291","author":"M Valiente","year":"2020","unstructured":"Valiente M, Van Swearingen AED, Anders CK, Bairoch A, Boire A, Bos PD, Cittelly DM, Erez N, Ferraro GB, Fukumura D, Gril B, Herlyn M, Holmen SL, Jain RK, Joyce JA, Lorger M, Massague J, Neman J, Sibson NR, Steeg PS, Thorsen F, Young LS, Vare\u0161lija D, Vultur A, Weis-Garcia F, Winkler F (2020) Brain metastasis cell lines panel: a public resource of organotropic cell lines. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-0291","journal-title":"Cancer Res"},{"issue":"12","key":"10055_CR27","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.Can-07-6307","volume":"68","author":"F Hilberg","year":"2008","unstructured":"Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68(12):4774\u20134782. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-6307","journal-title":"Cancer Res"},{"issue":"7","key":"10055_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676\u2013682. https:\/\/doi.org\/10.1038\/nmeth.2019","journal-title":"Nat Methods"},{"issue":"6","key":"10055_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2004.10.011","volume":"6","author":"F Winkler","year":"2004","unstructured":"Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6(6):553\u2013563. https:\/\/doi.org\/10.1016\/j.ccr.2004.10.011","journal-title":"Cancer Cell"},{"issue":"9","key":"10055_CR30","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1158\/0008-5472.Can-06-3316","volume":"67","author":"D Palmieri","year":"2007","unstructured":"Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K, Steeg PS (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67(9):4190\u20134198. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-3316","journal-title":"Cancer Res"},{"issue":"6 Pt 1","key":"10055_CR31","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1164\/ajrccm.152.6.8520790","volume":"152","author":"A Yuan","year":"1995","unstructured":"Yuan A, Yang PC, Yu CJ, Lee YC, Yao YT, Chen CL, Lee LN, Kuo SH, Luh KT (1995) Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 152(6 Pt 1):2157\u20132162. https:\/\/doi.org\/10.1164\/ajrccm.152.6.8520790","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10055_CR32","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s00066-014-0639-8","volume":"190","author":"AS Berghoff","year":"2014","unstructured":"Berghoff AS, Ilhan-Mutlu A, Wohrer A, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Melchardt T, Dome B, Heinzl H, Birner P, Preusser M (2014) Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases. Strahlenther Onkol 190(7):676\u2013685. https:\/\/doi.org\/10.1007\/s00066-014-0639-8","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"10055_CR33","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1111\/nan.12185","volume":"41","author":"AS Berghoff","year":"2015","unstructured":"Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Pichler J, Hutterer M, Melchardt T, Bartsch R, Zielinski CC, Birner P, Preusser M (2015) Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathol Appl Neurobiol 41(2):e41\u201355. https:\/\/doi.org\/10.1111\/nan.12185","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10055_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa038","author":"AS Berghoff","year":"2020","unstructured":"Berghoff AS, Breckwoldt MO, Riedemann L, Karimian-Jazi K, Loew S, Schlieter F, Furtner J, Cinci M, Thomas M, Strowitzki MJ, Marm\u00e9 F, Michel LL, Schmidt T, J\u00e4ger D, Bendszus M, Preusser M, Wick W, Winkler F (2020) Bevacizumab-based treatment as a salvage therapy in patients with recurrent symptomatic brain metastases. Neuro-Oncol Adv. https:\/\/doi.org\/10.1093\/noajnl\/vdaa038","journal-title":"Neuro-Oncol Adv"},{"issue":"2","key":"10055_CR35","doi-asserted-by":"publisher","first-page":"e000024","DOI":"10.1136\/esmoopen-2015-000024","volume":"1","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS, Schur S, Fureder LM, Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R, Preusser M (2016) Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open 1(2):e000024. https:\/\/doi.org\/10.1136\/esmoopen-2015-000024","journal-title":"ESMO Open"},{"key":"10055_CR36","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2147\/cmar.S188172","volume":"11","author":"Q Xu","year":"2019","unstructured":"Xu Q, Zhang Z, Chen Z, Zhang B, Zhao C, Zhang Y, Zhao C, Deng X, Zhou Y, Wu Y, Gu J (2019) Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice. Cancer Manage Res 11:2073\u20132085. https:\/\/doi.org\/10.2147\/cmar.S188172","journal-title":"Cancer Manage Res"},{"key":"10055_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1385\/1-59259-862-5:403","volume":"109","author":"I Krause","year":"2005","unstructured":"Krause I, Shoenfeld Y (2005) Intravenous immunoglobulin treatment for fibrosis, atherosclerosis, and malignant conditions. Methods Mol Med 109:403\u2013408. https:\/\/doi.org\/10.1385\/1-59259-862-5:403","journal-title":"Methods Mol Med"},{"issue":"2","key":"10055_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4161\/hv.27012","volume":"10","author":"M Sobieszczanska","year":"2014","unstructured":"Sobieszczanska M, Tubek S, Poplicha D, Grabelus A, Pawelczak J (2014) Henoch-Schonlein purpura (HSP) and high-dose immunoglobulin treatment in patient with familiar prostatic adenocarcinoma. Human Vaccines Immunother 10(2):358\u2013359. https:\/\/doi.org\/10.4161\/hv.27012","journal-title":"Human Vaccines Immunother"},{"issue":"1","key":"10055_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/WNO.0b013e31816754c4","volume":"28","author":"C Subhadra","year":"2008","unstructured":"Subhadra C, Dudek AZ, Rath PP, Lee MS (2008) Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuro-Ophthalmol 28(1):23\u201326. https:\/\/doi.org\/10.1097\/WNO.0b013e31816754c4","journal-title":"J Neuro-Ophthalmol"},{"issue":"9","key":"10055_CR40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s12094-006-0043-7","volume":"8","author":"M Murie-Fernandez","year":"2006","unstructured":"Murie-Fernandez M, Gurpide A, de la Cruz S, de Castro P (2006) Total remission of thymus carcinoma after treatment with intravenous immunoglobulin. Clin Transl Oncol 8(9):697\u2013699. https:\/\/doi.org\/10.1007\/s12094-006-0043-7","journal-title":"Clin Transl Oncol"},{"key":"10055_CR41","unstructured":"Corp. SA (2002) Normal serum, ascites, and cell supernatant typical immunoglobulin concentration ranges normal sera. https:\/\/www.sigmaaldrich.com\/content\/dam\/sigma-aldrich\/docs\/Sigma\/General_Information\/normalimmunoranges.pdf. Accessed 04 Jan 2019"},{"issue":"9","key":"10055_CR42","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/intimm\/dxp070","volume":"21","author":"M Damianovich","year":"2009","unstructured":"Damianovich M, Blank M, Raiter A, Hardy B, Shoenfeld Y (2009) Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg). Int Immunol 21(9):1057\u20131063. https:\/\/doi.org\/10.1093\/intimm\/dxp070","journal-title":"Int Immunol"},{"issue":"8","key":"10055_CR43","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/intimm\/11.8.1247","volume":"11","author":"Y Shoenfeld","year":"1999","unstructured":"Shoenfeld Y, Fishman P (1999) Gamma-globulin inhibits tumor spread in mice. Int Immunol 11(8):1247\u20131252","journal-title":"Int Immunol"},{"issue":"10","key":"10055_CR44","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.4049\/jimmunol.1303375","volume":"193","author":"A Dominguez-Soto","year":"2014","unstructured":"Dominguez-Soto A, de Casas-Engel M, Bragado R, Medina-Echeverz J, Aragoneses-Fenoll L, Martin-Gayo E, van Rooijen N, Berraondo P, Toribio ML, Moro MA, Cuartero I, Castrillo A, Sancho D, Sanchez-Torres C, Bruhns P, Sanchez-Ramon S, Corbi AL (2014) Intravenous immunoglobulin promotes antitumor responses by modulating macrophage polarization. J Immunol 193(10):5181\u20135189. https:\/\/doi.org\/10.4049\/jimmunol.1303375","journal-title":"J Immunol"},{"key":"10055_CR45","unstructured":"Hofmann I, Baum A, Hilberg F, Garin Chesa P, Depla E, Boucneau J, Kraut N, K\u00fcnkele K-P (2015) Dual targeting of angiogenesis pathways: combined blockade of VEGF and Ang2 signaling. 8th Euro Global Summit on Cancer Therapy, Valencia, Spain"},{"key":"10055_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fphar.2017.00193","volume":"8","author":"KA Bohn","year":"2017","unstructured":"Bohn KA, Adkins CE, Nounou MI, Lockman PR (2017) Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. Front Pharmacol 8:193. https:\/\/doi.org\/10.3389\/fphar.2017.00193","journal-title":"Front Pharmacol"},{"issue":"4","key":"10055_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/ncponc1066","volume":"5","author":"PS Steeg","year":"2008","unstructured":"Steeg PS, Theodorescu D (2008) Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5(4):206\u2013219. https:\/\/doi.org\/10.1038\/ncponc1066","journal-title":"Nat Clin Pract Oncol"},{"issue":"3","key":"10055_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-018-0134-8","volume":"16","author":"RL Anderson","year":"2019","unstructured":"Anderson RL, Balasas T, Callaghan J, Coombes RC, Evans J, Hall JA, Kinrade S, Jones D, Jones PS, Jones R, Marshall JF, Panico MB, Shaw JA, Steeg PS, Sullivan M, Tong W, Westwell AD, Ritchie JWA (2019) A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol 16(3):185\u2013204. https:\/\/doi.org\/10.1038\/s41571-018-0134-8","journal-title":"Nat Rev Clin Oncol"},{"key":"10055_CR49","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrc.2016.25","volume":"16","author":"PS Steeg","year":"2016","unstructured":"Steeg PS (2016) Targeting metastasis. Nat Rev Cancer 16:201. https:\/\/doi.org\/10.1038\/nrc.2016.25","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10055_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15(2):143\u2013155. https:\/\/doi.org\/10.1016\/s1470-2045(13)70586-2","journal-title":"Lancet Oncol"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-020-10055-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-020-10055-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-020-10055-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T23:14:41Z","timestamp":1631402081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-020-10055-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10055"],"URL":"https:\/\/doi.org\/10.1007\/s10585-020-10055-x","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,12]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FW received a research grant from Boehringer for conducting this work. FW also received research grants from Roche, Genentech, GSK, and Divide & Conquer Ltd. ASB, MOB, MAK, MP and BK have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}